Eugenia Girda
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Eugenia Girda has a total of 31 co-authors. Here are the top co-authors by number of shared publications:
- Fan Jin
Merck & Co., Inc., Rahway, NJ, USA
2 shared publications - Antoine Italiano
Gustave Roussy Cancer Institute, Paris-Saclay University, DITEP, Villejuif, France
1 shared publication - Antonio González-Martín
Medical Oncology Department, Clínica Universidad de Navarra, Madrid, Spain
1 shared publication - Bradley Robert Corr
Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, University of Colorado School of Medicine , Aurora, CO
1 shared publication Bristi Basu
Cancer Research UK Cambridge Centre, University of Cambridge, Cambridge, UK
1 shared publication- Chinyere E. Okpara
Eisai Ltd., Hatfield, United Kingdom
1 shared publication
Latest Publications
- Open Access
- 7 May 2024
- Published by Elsevier in Gynecologic Oncology
- Vol. 186, 182-190
Lenvatinib plus pembrolizumab for patients with previously treated advanced ovarian cancer: Results from the phase 2 multicohort LEAP-005 study
- 7 May 2024
- Published by Elsevier in Gynecologic Oncology
- Vol. 186, 182-190
Open AccessLenvatinib plus pembrolizumab for patients with previously treated advanced ovarian cancer: Results from the phase 2 multicohort LEAP-005 study
- 28 March 2022
- Published by Elsevier in Gynecologic Oncology
- Vol. 166 (2) , 211-218
Efficacy and safety of pembrolizumab for patients with previously treated advanced vulvar squamous cell carcinoma: Results from the phase 2 KEYNOTE-158 study
- 28 March 2022
- Published by Elsevier in Gynecologic Oncology
- Vol. 166 (2) , 211-218
Efficacy and safety of pembrolizumab for patients with previously treated advanced vulvar squamous cell carcinoma: Results from the phase 2 KEYNOTE-158 study
- Open Access
- 28 November 2018
- Published by IntechOpen
Management of High-Risk Obstetrical Patients with Morbidly Adherent Placenta in the Age of Resuscitative Endovascular Balloon Occlusion of the Aorta
Obstetric hemorrhage is the leading cause of maternal morbidity and mortality worldwide. At highest risk of massive obstetric hemorrhage, are women with morbidly adherent placenta (MAP). The complications associated with MAP are even more devastating in very high-risk obstetrical patients, where blood transfusion is not an option, either due to lack of resources or patient refusal, such as for Jehovah’s Witnesses. Resuscitative endovascular balloon occlusion of the aorta (REBOA) is a minimally-invasive technique used in trauma surgery to control non-compressible hemorrhage. REBOA is emerging as useful tool for managing high-risk obstetric surgery for MAP. This review aims to provide a framework for use of REBOA in obstetric care in challenging circumstances.
- 28 November 2018
- Published by IntechOpen
Open AccessManagement of High-Risk Obstetrical Patients with Morbidly Adherent Placenta in the Age of Resuscitative Endovascular Balloon Occlusion of the Aorta
Obstetric hemorrhage is the leading cause of maternal morbidity and mortality worldwide. At highest risk of massive obstetric hemorrhage, are women with morbidly adherent placenta (MAP). The complications associated with MAP are even more devastating in very high-risk obstetrical patients, where blood transfusion is not an option, either due to lack of resources or patient refusal, such as for Jehovah’s Witnesses. Resuscitative endovascular balloon occlusion of the aorta (REBOA) is a minimally-invasive technique used in trauma surgery to control non-compressible hemorrhage. REBOA is emerging as useful tool for managing high-risk obstetric surgery for MAP. This review aims to provide a framework for use of REBOA in obstetric care in challenging circumstances.